Discover 476 paid clinical trials in Grand Rapids, Michigan. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.
Filter
2
Filter results
Results: 476
A Study of APG-3288 in Relapsed/Refractory Blood Cancers
for
Relapsed/Refractory Hematological Malignancies,
Location: Grand Rapids MI, East Brunswick NJ, Los Angeles CA
Sponsor: Ascentage Pharma Group Inc.
Sex: All
Age: 18+
Code: NCT07424833
Phase1, Recruiting
A Study to Investigate the Safety and Efficacy of KQB548 in Participants With Advanced Solid Malignancies
for
Solid Tumor Malignancies
Location: Grand Rapids MI, Cincinnati OH, Fairfax VA, Irving TX,
Sponsor: Kumquat Biosciences Inc.
Sex: All
Age: 18+
Code: NCT07207707
Phase1, Recruiting
TLN-372 in Advanced KRAS Mutant Solid Tumors
for
KRAS Mutant Solid Tumors
Location: Grand Rapids MI, Toronto, St Louis MO, Nashville TN,
Sponsor: Treeline Biosciences, Inc.
Sex: All
Age: 18+
Code: NCT07204340
Phase1, Recruiting
A Study of ZW251 in Participants With Advanced Solid Tumors
for
Hepatocellular Carcinoma,
Location: Grand Rapids MI, Louisville KY, Hackensack NJ,
Sponsor: Zymeworks BC Inc.
Sex: All
Age: 18+
Code: NCT07164313
Phase1, Recruiting
A Study of JNJ-95804306 for Relapsed or Refractory Hematological Malignancies
for
Hematologic Neoplasms
Location: Grand Rapids MI, Indianapolis IN, Nashville TN,
Sponsor: Janssen Research & Development, LLC
Sex: All
Age: 18+
Code: NCT07572006
Phase1, Recruiting
Interested in new trials?
Get alerts for new trials in your area by subscribing now
A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors
for
Advanced Solid Tumor
Location: Grand Rapids MI, Detroit MI, Madison WI, Cleveland OH,
Sponsor: BioNTech SE
Sex: All
Age: 18+
Code: NCT07070232
Phase1, Phase2, Recruiting
A Study to Assess the Safety, Tolerability, and Antileukemic Activity of Debio 1562M in Participants With Acute Myeloid Leukemia (AML)
for
Acute Myeloid Leukemia
Location: Grand Rapids MI, Chicago IL, Columbus OH, Buffalo NY,
Sponsor: Debiopharm International SA
Sex: All
Age: 18+
Code: NCT06969430
Phase1, Phase2, Recruiting
Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors
for
Head and Neck Squamous Cell Carcinoma (HNSCC),
Location: Grand Rapids MI, Columbus OH, New York NY,
Sponsor: Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.
Sex: All
Age: 18+
Code: NCT05985655
Phase1, Phase2, Recruiting
A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid Tumors
for
Gastric or Gastro-esophageal Junction (GEJ) Adenocarcinoma,
Location: Grand Rapids MI, Indianapolis IN, Fairfax VA, Durham NC,
Sponsor: Astellas Pharma Global Development, Inc.
Sex: All
Age: 18+
Code: NCT07488676
Phase1, Phase2, Recruiting
TLN-121 in Relapsed or Refractory Non-Hodgkin Lymphomas
for
Lymphoma, Lymphoma, Non Hodgkin
Location: Grand Rapids MI, St Louis MO, Nashville TN,
Sponsor: Treeline Biosciences, Inc.
Sex: All
Age: 18+
Code: NCT07082803
Phase1, Recruiting
A Clinical Study to Test if an Investigational Treatment Called BNT314 When Used in Combination With Another Investigational Treatment Pumitamig (BNT327) and Chemotherapy, is Beneficial and Safe for Patients With Advanced Colorectal Cancer
for
Metastatic Colorectal Cancer
Location: Grand Rapids MI, Cleveland OH, New Haven CT, Houston TX
Sponsor: BioNTech SE
Sex: All
Age: 18+
Code: NCT07079631
Phase1, Phase2, Recruiting
Study of AUBE00 in Patients With Solid Tumors
for
Solid Tumors
Location: Grand Rapids MI, Houston TX
Sponsor: Chugai Pharmaceutical
Sex: All
Age: 18+
Code: NCT07030959
Phase1, Recruiting
A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors
for
HR+ Breast Cancer, Triple Negative Breast Cancer (TNBC),
Location: Grand Rapids MI, Cleveland OH, Iowa City IA,
Sponsor: NiKang Therapeutics, Inc.
Sex: All
Age: 18+
Code: NCT07029399
Phase1, Recruiting
AVA6103 in Subjects With Locally Advanced or Metastatic Selected Solid Tumors